GHK-Cu
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
GHK-Cu is not a growth factor. It is a coordination complex – a three-amino-acid tripeptide, glycine-histidine-lysine, that binds cupric copper with high affinity and presents it to cell-surface receptors and nuclear machinery in a biologically legible form. Its mechanism is less a single pathway than a vocabulary: a set of signals that shift tissue from a state of breakdown toward a state of reconstruction. The literature describes effects on more than 4,000 human genes – roughly 30 percent upregulated toward repair, roughly 30 percent downregulated away from inflammation and degradation. What follows is a reading of the principal chapters.
GHK coordinates Cu²⁺ through its histidine imidazole and terminal amine, masking ionic copper’s cytotoxicity while donating it to SOD1, cytochrome c oxidase, and lysyl oxidase. Restored cuproenzyme activity improves mitochondrial respiration, antioxidant capacity, and collagen cross-linking simultaneously.
TGF-β1 upregulation in fibroblasts drives transcription of collagen I, collagen III, and elastin while suppressing MMP-1 and MMP-8 in chronic wound environments. The result is rebalanced synthesis-to-degradation rather than blanket matrix suppression.
NF-κB attenuation reduces transcription of IL-6, TNF-α, and IL-1β through a glucocorticoid-independent mechanism. Genome-wide analysis identified GHK-Cu as a broad regulator of inflammation-associated gene clusters, with particular suppression of fibrotic and senescence-linked pathways.
Nrf2 nuclear translocation drives binding to antioxidant response elements in the promoters of HO-1, glutathione S-transferase, and NQO1. This copper-independent cytoprotective axis intersects with autophagy regulation and maps to neuroprotective signals observed in preclinical models.
What we observe
What changed in skin and healing
GHK-Cu has been studied across wound healing, dermal remodeling, neuroprotection, and systemic antioxidant defense. The strongest signals come from controlled topical trials and in vitro fibroblast work. Subcutaneous systemic data remain promising in animal models but sparse in human cohorts.
01
Wound Closure
02
Collagen and Elastin
03
Oxidative Stress Reduction
04
Inflammatory Cytokine Reduction
05
Neuroprotective Signaling
06
Skin Density Texture
Evidence
What research shows
The evidentiary base is broad in scope and shallow in clinical depth. Decades of in vitro and animal work have mapped the mechanism with considerable precision. Controlled human trials remain concentrated in topical dermatology, and the three entries below represent the most cited contributions across the compound’s research arc.
GHK-Cu stimulates collagen synthesis and fibroblast proliferation in human skin equivalent models
Human fibroblasts cultured in three-dimensional collagen lattices and treated with GHK-Cu at 1–100 nM concentrations showed dose-dependent increases in procollagen I mRNA and secreted collagen protein. Elastin fiber organization was improved relative to untreated controls. The authors noted a biphasic dose-response, with maximal effect near 1 nM and diminishing returns above 1 µM – a pattern consistent with receptor saturation rather than simple mass-action kinetics.
GHK and DNA: resetting the human genome to health - a broad-spectrum gene regulatory analysis
Bioinformatic analysis of publicly available gene expression datasets identified GHK as a modulator of 4,033 human genes, with 31% upregulated and 33% downregulated relative to untreated baselines. Pathway enrichment analysis showed strong representation of wound repair, antioxidant defense, and anti-inflammatory clusters among upregulated genes, and fibrosis, oncogenic signaling, and cellular senescence pathways among downregulated genes. The authors proposed GHK as a systemic tissue-remodeling signal rather than a tissue-specific growth factor.
Topical GHK-Cu in the treatment of skin aging: a randomized, double-blind, vehicle-controlled trial
Sixty-seven subjects aged 45–65 received either 1% GHK-Cu cream or vehicle twice daily for 12 weeks. Blinded dermatologist assessment and optical profilometry showed statistically significant improvements in skin laxity, fine-line depth, and surface roughness in the active arm. Punch biopsy specimens from a subset of 20 subjects demonstrated increased dermal collagen density by histomorphometry. No systemic absorption was detected by plasma assay, and no serious adverse events were recorded.
From lyophilized powder to a usable solution.
Peptide
50 mg lyophilized powder
Diluent
3.0 mL sterile water
Final concentration
16.67 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Schedule below mirrors the peptidedosages.com educational protocol (typical daily range: 1.0–2.0 mg per injection (most common protocols use 5 days/week or 3×/week)).
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: store at −20 °C (−4 °F) or below.
- Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days.
- The blue-green color of reconstituted solution is normal and confirms intact copper chelation · discard if solution becomes colorless, precipitates, or turns turbid
- Protect from UV light at all stages · copper-peptide complexes are photosensitive in solution · amber vials or foil wrapping recommended
- Do not expose to temperatures above 25 °C for extended periods · brief room-temperature exposure during reconstitution is acceptable
Side effects
What members describe
- Injection-site reactions - mild erythema, transient stinging, or blue-green skin discoloration at the injection site · typically resolves within 24–48 hours · rotate sites
- Metallic taste - reported anecdotally following subcutaneous administration · attributed to systemic copper release · transient and dose-related
- Nausea - infrequent · observed at higher doses in animal models · reduce dose if gastrointestinal discomfort occurs
- Headache - reported in a minority of users at higher doses · mechanism unclear · monitor and reduce dose if persistent
- Copper accumulation risk with prolonged high-dose use - theoretical concern in individuals with impaired copper metabolism · periodic serum copper and ceruloplasmin monitoring is prudent in extended protocols
Contradictions
Reasons to abstain
- Wilson's disease or any confirmed disorder of copper metabolism · GHK-Cu delivers bioavailable copper and is absolutely contraindicated in these conditions
- Known hypersensitivity to copper compounds or any component of the formulation
- Active malignancy - GHK-Cu upregulates angiogenic and proliferative gene programs; use in oncology contexts requires specialist oversight and is not supported by current evidence
- Pregnancy and lactation - no safety data exist; systemic copper delivery in pregnancy carries theoretical developmental risk
- Concurrent use of copper-chelating agents (e.g., penicillamine, trientine) - pharmacological antagonism expected; combined use is not rational without specialist guidance
Synergies
What to use with GHK-Cu
GHK-Cu occupies the tissue-remodeling and antioxidant pillar. Its most coherent companions are peptides that address inflammation, cellular repair, or structural matrix support through distinct but convergent pathways. The combinations below reflect mechanistic logic, not clinical trial data. No stacking protocol has been validated in human research.
FAQ
Your questions, patiently answered
The distinction is specificity of delivery. Free copper salts are cytotoxic at concentrations that GHK-Cu tolerates well, because the tripeptide coordinates the ion into a stable, cell-recognizable complex. The peptide carrier is not inert – it engages its own receptor interactions and gene-regulatory effects independent of copper delivery. GHK-Cu is therefore a bifunctional molecule: a copper chaperone and a signaling peptide simultaneously.
Only partially. Topical studies establish that GHK-Cu is biologically active at the tissue level and that its collagen and anti-inflammatory signals are real. They do not establish systemic pharmacokinetics, bioavailability by injection, or the dose-response relationship for subcutaneous administration. The mechanisms are likely conserved, but the magnitude and distribution of effect may differ substantially. Extrapolation should be made with care.
In vitro data consistently show maximal effect at low nanomolar concentrations, with diminishing or occasionally reversed effects at higher concentrations. This is characteristic of peptides that act through saturable receptors. In practical terms, it argues against the intuition that more is better – a lower, more physiological dose may produce a stronger signal than a high one. This is one reason the dosing framework above errs toward conservative ranges.
It is significant as a hypothesis-generating observation, not as a clinical claim. The Pickart and Margolina bioinformatic analysis identified GHK as a statistical correlate of broad gene expression patterns in publicly available datasets. It does not establish that GHK-Cu causes those changes in vivo in humans, nor does it specify which effects are therapeutically relevant. The finding is best read as a map of biological plausibility – a reason to investigate further, not a summary of proven outcomes.
Theoretically, yes, with prolonged high-dose use. The daily recommended intake of copper for adults is approximately 0.9 mg; research doses of GHK-Cu in the 1–3 mg range deliver a fraction of that as chelated copper. At moderate doses and cycle lengths, accumulation is unlikely in individuals with normal copper metabolism. Wilson’s disease and related disorders represent absolute contraindications. Periodic monitoring of serum copper and ceruloplasmin is a reasonable precaution in any extended protocol.
Aeterna does not prescribe, dispense, or sell any compound, including GHK-Cu. This monograph is an educational document – a translation of the available literature into a coherent framework for informed conversation with a qualified physician. Sourcing, prescribing, and clinical decision-making remain entirely outside our practice.
In the same family
Further reading in the curriculum - adjacent peptides in the regenerative and antioxidant literature.
Sourcing · Independently verified
When you're ready, source thoughtfully.